Microbix Unveils Test Controls for Head and Neck Cancer
MISSISSAUGA, Ontario, March 11, 2024 (GLOBE NEWSWIRE) — Microbix Biosystems Inc. (TSX:MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that it is presenting results of Quality Assessment Products (“QAPs™”) for supporting the quality control (“QC”) of histology and PCR-based tests driven by tissue-samples of Head and Neck cancer caused by human papilloma virus (“HPV”). Its results presentation will be made at EUROGIN 2024, an international collaborative conference and exhibition focused upon innovations in HPV research and global cancer solutions taking place in Stockholm, Sweden from March 13 to 16, 2024.